ResMed (RMD) CFO Brett Sandercock reports direct holding of 83,495 shares

Rhea-AI Filing Summary

ResMed Inc.’s Chief Financial Officer Brett Sandercock reported his direct ownership of ResMed Common Stock. Following the reported information, he directly holds 83,495 shares of common stock. The filing reflects his updated ownership position without detailing any specific buy or sell transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sandercock Brett

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock — 83,495 shares (Direct, null)

Footnotes (1)

Key Figures

Direct common shares held: 83,495 shares

1 metrics

Direct common shares held 83,495 shares Total ResMed Common Stock directly owned following reported information

Key Terms

ResMed Common Stock, Form 4, direct or indirect

3 terms

ResMed Common Stock financial

"security_title": "ResMed Common Stock""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

direct or indirect financial

"direct_or_indirect": "D""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandercock Brett

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CALIFORNIA 92123

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock								83,495	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The reporting person ceased to serve as an officer due to retirement effective May 4, 2026.

	/s/ Brett Sandercock, Chief Financial Officer	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What does ResMed (RMD) CFO Brett Sandercock’s latest Form 4 show?

The Form 4 shows CFO Brett Sandercock directly holds 83,495 shares of ResMed Common Stock. The entry is coded as a holding update, with no explicit buy or sell transaction reported in this filing.

How many ResMed (RMD) shares does the CFO hold after this Form 4?

After the reported information, CFO Brett Sandercock directly owns 83,495 shares of ResMed Common Stock. This figure represents his direct holding as disclosed, without indicating any new purchase or sale activity.

Does this ResMed (RMD) Form 4 show the CFO buying or selling shares?

The filing does not specify a buy or sell transaction. It records an updated holding entry for CFO Brett Sandercock, indicating he directly owns 83,495 shares of ResMed Common Stock following the reported information.

Who is the insider named in this ResMed (RMD) Form 4 filing?

The insider is Brett Sandercock, the Chief Financial Officer of ResMed Inc. The filing reports his direct ownership position in ResMed Common Stock, showing 83,495 shares held after the reported information.

Is the ResMed (RMD) CFO’s ownership in this Form 4 direct or indirect?

The Form 4 shows the CFO’s ownership as direct, marked with ownership code “D.” It reports that Brett Sandercock directly holds 83,495 shares of ResMed Common Stock rather than through an intermediary entity.